Healthcare
(ISRG) Intuitive Surgical 2011 Fourth Quarter Earnings Scorecard
Intuitive Surgical (ISRG) reported favorable fourth-quarter 2011 results. Earnings per share came in at $3.75, beating the Zacks Consensus Estimate of $3.34 and the year-ago earnings of $3.02. Net income...
(ISRG) Now is the Time to Buy Healthcare Stocks
I’ve been talking a lot lately about the $4 trillion that’s about to fall into the laps of businesses in the healthcare sector due to the number of Baby Boomers who are now turning 65.
And we know that the older we get, the more we spend on healthcare.
Consider:
- The...
2Feb2012 | InvestmentU | 0 comments | Continued
(WLP) These Healthcare Insurance Stocks Are Ready to Rise
by Marc Lichtenfeld, Healthcare Expert
Wednesday, February 24, 2010: Issue...
(MYL) Mylan Incorporated – Bull of the Day
Mylan, Inc. (MYL) is one of the leading players in the US generics market. The company holds immense potential as many blockbuster drugs have begun to go off-patent and many more will lose patent exclusivity...
(ZOLL) ZOLL Medical Corporation – Bull of the Day
We retain our Outperform recommendation on ZOLL Medical Corp. (ZOLL) following its forecast-topping first quarter results. Revenues and earnings for the quarter beat the Zacks Consensus Estimates, driven...
(UNH) UnitedHealth Group – Bull of the Day
UnitedHealth Group’s (UNH) fourth-quarter 2011 earnings came in substantially ahead of the Zacks Consensus Estimate, led by strong revenue growth from the UnitedHealthcare and Optum businesses, partially...
(DVA) DaVita Incorporated – Bull of the Day
We are upgrading our recommendation on DaVita, Inc. (DVA) to Outperform based on the company’s strong cash flows and strategic acquisitions. The new bundled ESRD payment system is also expected to be...
(ISRG) Intuitive Squarely Beats Earnings Expectations
Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2011 earnings per share of $3.75 and $12.32, respectively, beating the Zacks Consensus Estimates of $3.34 and $11.89, respectively, while surpassing...
(ABT) Earnings Season in Full Swing – Earnings Preview
Earnings Preview 1/20/12
Earnings season will be in full swing this week. 422 firms are scheduled to report, and 117 of those will be members of the S&P 500. By the end of the week we should have...
(JNJ) Mixed Earnings, Greece May Slip Markets
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports...
(JNJ) Jan 24: Day of Earnings! – Economic Highlights
With nothing major on the domestic economic calendar, headlines about Greece’s as-yet unsuccessful negotiations with its bondholders to restructure its private debt may get some traction. But today’s market action will be mostly about the slew of mixed earnings reports...
(UNH) UnitedHealth Group – Bull of the Day
UnitedHealth Group’s (UNH) fourth-quarter 2011 earnings came in substantially ahead of the Zacks Consensus Estimate, led by strong revenue growth from the UnitedHealthcare and Optum businesses, partially...
(HS) HealthSpring Shareholders Approve CIGNA Merger
The acquisition of HealthSpring Inc. (HS) by CIGNA Corp. (CI) has received the approval of the former company’s shareholders. The approval...
(BIIB) Biogen Analyst Neutral on Shares
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will continue to retain...
(ILMN) Two Major Biotech Trends In 2012
by Marc Lichtenfeld, Investment U Senior...
(CELG) Celgene Corporation – Bull of the Day
We are maintaining our Outperform recommendation on Celgene Corp. (CELG) following impressive preliminary results disclosed for the fourth quarter (adjusted EPS up 46%) and full year 2011 (adjusted EPS up...
(ARQL) Company News for January 18, 2012 – Corporate Summary
• Bio technology company ArQule Inc.’s (NASDAQ:ARQL) share prices gained 11.91% to close at $6.67 after the company’s experimental treatment for liver cancer reported a positive outcome in its Phase II trial
• ...
(VPHM) ViroPharma Drug Earns Priority Review
ViroPharma Inc. (VPHM) recently announced that the Canadian regulatory body has granted priority review status to the company’s new drug submission (NDS) for Cinryze. ViroPharma is seeking the drug’s...
(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight...
(ITMN) InterMune Fourth Quarter Esbriet Sales Snapshot
InterMune, Inc. (ITMN) recently reported preliminary fourth quarter...
(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals
The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&A) deals have...
(BMY) Company News for January 04, 2012 – Corporate Summary
• Share prices of natural gas producer Devon Energy Corp (NYSE:DVN) gained 6.63% after the company announced it would sell a stake in five of its exploratory projects across the U.S., to Sinopec International Petroleum...
(STJ) New Year Bets from MedTech
Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean.
The U.S. economy continues to be cramped by a spate of headwinds including a still...
(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic...
(JNJ) Pharma & Biotech Stock Review & Outlook – Industry Outlook
With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a...
(TEVA) Teva Pharmaceutical Industries Provides In-Line 2012 Outlook
Teva Pharmaceutical Industries Ltd. (TEVA) recently provided guidance for 2012. The company expects to earn $5.48 and $5.68 per share on total net sales of about $22 billion. Guidance was generally in line...
(BMY) Bristol-Myers Squibb Sees Pipeline Setback
Bristol-Myers Squibb Company (BMY) recently suffered a pipeline setback with its oncology candidate, brivanib, performing disappointingly in a late-stage study (BRISK-PS). The study evaluated brivanib as a...
(AET) Health Insurance Stock Review – December 2011 – Industry Outlook
The Health and Medical Insurance industry is an integral part of the U.S. economy. According to the Centers for Medicare and Medicaid Services, U.S. health expenditures account for about 18% of U.S. GDP. Money spent per person on healthcare in the United States is more than...
(MR) Mindray Medical International Limited Acquires IT Firm in China
Mindray Medical International Limited (MR), a leading Chinese medical device manufacturer, recently revealed an agreement to take a majority stake in Zhejiang Greenlander Information Technology Co., Ltd. (“Greenlander”)....
(OPTR) Optimer Pharmaceuticals Dificlir Cleared in European Union
Optimer Pharmaceuticals, Inc. (OPTR) and partner Astellas Pharma recently announced that their antibiotic Dificlir received approval in the European Union (EU), not belying expectations. The European Medicines...